Silence Therapeutics (SLN) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

SLN · Stock Price

USD 6.95+3.12 (+81.46%)

Market Cap: $325.9M

Historical price data

Market Cap: $325.9MPipeline: 7 drugsFounded: 1994Employees: 100-250HQ: London, United Kingdom

Sector Ranking#17 in RNA Therapeutics (non-mRNA)#63 in Rare & Orphan Diseases

Overview

Silence Therapeutics is a UK-based pioneer in RNA interference (RNAi) therapeutics, utilizing its proprietary mRNAi GOLD™ platform to design targeted siRNA medicines. The company has validated its technology through significant partnerships with AstraZeneca and Hansoh Pharma, while advancing its internal lead asset, zerlasiran (SLN360), for cardiovascular disease. Its strategy balances internal pipeline development in cardiometabolic and hematologic diseases with platform licensing, aiming to create a sustainable biotech with multiple value inflection points.

CardiovascularMetabolicHematologic

Technology Platform

Proprietary mRNAi GOLD™ platform for the design and delivery of GalNAc-conjugated short interfering RNAs (siRNAs) enabling potent, durable, and targeted gene silencing in hepatocytes.

Pipeline

7

7 drugs in pipeline

Drug	Indication	Stage
SLN360 + Placebo	Cardiovascular Diseases	Phase 2
SLN124 + Placebo	Polycythemia Vera	Phase 1/2
Atu027 & gemcitabine in lead in safety period + Atu027 & gem...	Carcinoma, Pancreatic Ductal	Phase 1/2
Atu027	Advanced Solid Tumors	Phase 1
SLN124 + Placebo	Non-transfusion-dependent Thalassemia	Phase 1

Funding History

2

Total raised:$40M

PIPE$40MUndisclosedJul 15, 2020

IPOUndisclosedUndisclosedJun 15, 2005

Opportunities

First-in-class potential for zerlasiran in the vast, untreated elevated Lp(a) population represents a multi-billion dollar opportunity.

The platform partnership model provides validated, non-dilutive funding and future royalty streams across a wide range of liver-targeted diseases.

Risk Factors

Lead candidate faces intense competition in the Lp(a) space from large pharma players.

Clinical failure of key assets would severely impact valuation.

The company remains pre-commercial and dependent on partnership success and future financing.

Competitive Landscape

Operates in the competitive RNAi therapeutics arena, with direct competition in Lp(a) from Amgen, Novartis/Ionis, and Eli Lilly. Platform competes with leaders like Alnylam, but differentiation is achieved through proprietary chemistry and validated by high-profile partnerships.